The circulating tumor cells (CTC) market is expected to register a CAGR of 9.5% during the forecast period.
The COVID-19 pandemic is an unprecedented health concern impacting the tumor ablation market. With the pandemic still in the growth phase, it has become difficult to establish a long-term impact on the tumor ablation market. The market witnessed changes during the first quarter of 2020 with the onset of the pandemic.
The COVID-19 pandemic affected healthcare systems globally and resulted in the interruption of usual care in many healthcare facilities, exposing vulnerable patients with cancer to significant risks. For instance, a study titled ‘Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study’ in 2020 reported that A total of 356 centers from 54 countries across six continents participated between April 21 and May 8, 2020. These centers serve 716,979 new patients with cancer a year. Most of them (88.2%) reported facing challenges in delivering care during the pandemic. Although 55.34% reduced services as part of a preemptive strategy, other common reasons included an overwhelmed system (19.94%), lack of personal protective equipment (19.10%), and staff shortage (17.98%), and restricted access to medications (9.83%). Thus, this indicates that due to COVID-19, there were disruptions in cancer care regarding reduced chemotherapy and radiotherapy services and ongoing research and development studies, thereby impacting the market growth.
Additionally, the study "Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal Cancer," published in September 2021, evaluated the effect of COVID-19-induced lockdown on newly diagnosed colorectal cancer cases through circulating tumor DNA and reported that tumor burden in patients was significantly higher who received a diagnosis after lockdown compared with those who were diagnosed before lockdown. This study indicated that tumor burden increased during COVID-19, significandramatically market growth.
The significant factors for the growth of the circulating tumor cells (CTC) market include the advancements in biomedical imaging and bioengineering technology, the rising demand for preventive medicine and companion diagnostics, and the growing prevalence of cancer.
The global cancer burden is increasing; thus, cancer therapies must be modified according to regional and national priorities. For instance, according to the September 2021 update by the World Health Organization (WHO), cancer accounted for approximately 10 million worldwide deaths in 2020. The most common in 2020 (in terms of new cases of cancer) were: breast (2.26 million cases); lung (2.21 million cases); colon and rectum (1.93 million cases); prostate (1.41 million cases); skin (non-melanoma) (1.20 million cases); and stomach (1.09 million cases).
In addition, As per the 2020 statistics by GLOBOCAN 2020, 19,292,789 people were diagnosed with cancer in 2020. As per the same source mentioned above, the number of people with cancer is estimated to reach 30.2 million by 2040. The increasing cancer burden is due to several factors, such as population growth and aging and the changing prevalence of specific causes of cancer linked to social and economic development. For instance, as per the World Health Organization (WHO), in September 2021, about one-third of deaths from cancer are due to tobacco use, high body mass index, alcohol use, low fruit and vegetable intake, and lack of physical activity. Thus, the increasing tobacco consumption is expected to cause an increase in the prevalence of cancer, thereby contributing to the market growth.
Moreover, recent studies in the market will boost its potential, leading to significant market growth. For instance, a study was initiated in February 2021 to evaluate the ability of heat shock protein HSP70 to isolate and quantify circulating tumor cells (CTCs) in patients with advanced or metastatic tumors. This study is expected to be completed by May 2022. Positive results from such studies will boost the market.
Thus, owing to the factors above, the studied market is expected to grow significantly during the study period. However, technical difficulties in the detection and characterization of CTCs associated with the high cost of diagnosis and lack of awareness and unwillingness to adopt advanced CTC technologies are expected to hamper the market growth further.
In the case of the positive enrichment method, it cannot isolate CTCs depending on heterogeneous properties. Still, the harmful enrichment method can isolate heterogeneous and intact CTCs by precisely eliminating blood cells. The rising prevalence of the various types of cancer is expected to drive the market's overall growth.
According to the article published in Mindspace Oncology 2021, in 2020, liver cancer was the sixth most common cancer and the third leading cause of cancer deaths worldwide, with an estimated 905,677 new cases and 830,180 deaths. East Asia had the highest incidence, at 17.9 per 100,000 (26.9 in males and 8.9 in females), followed by Micronesia, northern Africa, Southeast Asia, and Melanesia. Moreover, the incidence rate was 6.9 per 100,00 in North America and 5.6 per 100,000 in western Europe. Overall, the incidence rate of liver cancer is approximately three times higher in males than in females.
Furthermore, according to an article published by the American Cancer Society in January 2022, kidney cancer is among the ten most common cancers in both men and women in the United States. Overall, the lifetime risk for developing kidney cancer in men is about 1 in 46, and in women is about 1 in 80, which is significantly high. Cancer prevention is one of the most significant challenges with this growing burden. The analysis of circulating tumor cells is a substantial aspect of monitoring disease progression or response to treatment, specifically as a companion diagnostic for new anticancer drugs and research into the mechanisms of disease progression.
In addition, negative enrichment has advantages over positive enrichment in isolating CTCs, owing to which the segment is expected to witness high growth over the forecast period. For instance, the study "Negative enrichment of circulating tumor cells from unmanipulated whole blood with a 3D printed device," published in October 2021, stated that the negative enrichment approach is advantageous because it leads to an unbiased detection of CTCs and also produces intact tumor cells free of attached immuno-agents, eliminating potential artifacts in downstream studies. Thus, the market is harmful to grow significantly with the advantages of negative enrichment methods over other enrichment approaches.
Thus, the studied segment is expected to contribute significantly to the market growth owing to the abovementioned factors.
North America is expected to contribute to the significant growth of the market owing to the factors such as the increasing burden of cancer, product approvals, and rising research and development activities.
For instance, according to the estimates of the 2022 American Cancer Society, Inc., about 236,740 new cases of lung cancer will be diagnosed in the country in 2022. The same source also states that 79,000 new cases of kidney cancer and 13,920 deaths will be reported in 2022 from Kidney cancer. The high burden of cancer is expected to boost the demand for CTC detection kits, thereby driving the market growth.
Additionally, product approvals in the studied market are further expected to drive market growth. For instance, in November 2020, the Food and Drug Administration (FDA) expanded the approved uses for a blood test, known as a liquid biopsy, that can help doctors pick the best treatments for some people with cancer. The test identifies cancer-related genetic changes in DNA from tumor cells released into the blood.
According to a study, "Cancer cells alter protein production machinery to hasten metastasis," published in February 2020, CTCs enriched from the blood of breast cancer patients have higher levels of ribosomal proteins (RP), and their presence is associated with increased disease aggressiveness and poor clinical outcomes. Thus, studies evaluating the presence of ribosomal proteins in CTCs will lead to an effective cancer diagnosis, thus, driving the market.
The United States has one of the highly successful products, the CellSearch Circulating Tumor Cell Kit, which was approved by the US Food and Drug Administration (FDA). The product has reimbursement facilities through various public and private payers in several states, such as Cigna Government Services, Noridian, and United Healthcare. Several universities across the United States have relied on CTCs applications to advance the practice of pathology and laboratory medicine. Thus, the market studied is expected to witness high growth over the forecast period owing to all the factors above.
The market studied is a moderately consolidated market, owing to the presence of small and large market players. Some market players are Advanced Cell Diagnostics Inc., Aviva Biosciences, Biocept Inc., Creatv Micro Tech, Inc., LungLife AI Inc., Menarini Silicon Biosystems, and Miltenyi Biotec, Precision For Medicine (Formerly ApoCell), and Qiagen NV.
This product will be delivered within 2 business days.
The COVID-19 pandemic is an unprecedented health concern impacting the tumor ablation market. With the pandemic still in the growth phase, it has become difficult to establish a long-term impact on the tumor ablation market. The market witnessed changes during the first quarter of 2020 with the onset of the pandemic.
The COVID-19 pandemic affected healthcare systems globally and resulted in the interruption of usual care in many healthcare facilities, exposing vulnerable patients with cancer to significant risks. For instance, a study titled ‘Impact of the COVID-19 Pandemic on Cancer Care: A Global Collaborative Study’ in 2020 reported that A total of 356 centers from 54 countries across six continents participated between April 21 and May 8, 2020. These centers serve 716,979 new patients with cancer a year. Most of them (88.2%) reported facing challenges in delivering care during the pandemic. Although 55.34% reduced services as part of a preemptive strategy, other common reasons included an overwhelmed system (19.94%), lack of personal protective equipment (19.10%), and staff shortage (17.98%), and restricted access to medications (9.83%). Thus, this indicates that due to COVID-19, there were disruptions in cancer care regarding reduced chemotherapy and radiotherapy services and ongoing research and development studies, thereby impacting the market growth.
Additionally, the study "Association of COVID-19 Lockdown With the Tumor Burden in Patients With Newly Diagnosed Metastatic Colorectal Cancer," published in September 2021, evaluated the effect of COVID-19-induced lockdown on newly diagnosed colorectal cancer cases through circulating tumor DNA and reported that tumor burden in patients was significantly higher who received a diagnosis after lockdown compared with those who were diagnosed before lockdown. This study indicated that tumor burden increased during COVID-19, significandramatically market growth.
The significant factors for the growth of the circulating tumor cells (CTC) market include the advancements in biomedical imaging and bioengineering technology, the rising demand for preventive medicine and companion diagnostics, and the growing prevalence of cancer.
The global cancer burden is increasing; thus, cancer therapies must be modified according to regional and national priorities. For instance, according to the September 2021 update by the World Health Organization (WHO), cancer accounted for approximately 10 million worldwide deaths in 2020. The most common in 2020 (in terms of new cases of cancer) were: breast (2.26 million cases); lung (2.21 million cases); colon and rectum (1.93 million cases); prostate (1.41 million cases); skin (non-melanoma) (1.20 million cases); and stomach (1.09 million cases).
In addition, As per the 2020 statistics by GLOBOCAN 2020, 19,292,789 people were diagnosed with cancer in 2020. As per the same source mentioned above, the number of people with cancer is estimated to reach 30.2 million by 2040. The increasing cancer burden is due to several factors, such as population growth and aging and the changing prevalence of specific causes of cancer linked to social and economic development. For instance, as per the World Health Organization (WHO), in September 2021, about one-third of deaths from cancer are due to tobacco use, high body mass index, alcohol use, low fruit and vegetable intake, and lack of physical activity. Thus, the increasing tobacco consumption is expected to cause an increase in the prevalence of cancer, thereby contributing to the market growth.
Moreover, recent studies in the market will boost its potential, leading to significant market growth. For instance, a study was initiated in February 2021 to evaluate the ability of heat shock protein HSP70 to isolate and quantify circulating tumor cells (CTCs) in patients with advanced or metastatic tumors. This study is expected to be completed by May 2022. Positive results from such studies will boost the market.
Thus, owing to the factors above, the studied market is expected to grow significantly during the study period. However, technical difficulties in the detection and characterization of CTCs associated with the high cost of diagnosis and lack of awareness and unwillingness to adopt advanced CTC technologies are expected to hamper the market growth further.
Key Market Trends
The Negative Enrichment Segment is is Expected to Hold a Major Market Share in the Circulating Tumor Cells (CTC) Market
In the case of the positive enrichment method, it cannot isolate CTCs depending on heterogeneous properties. Still, the harmful enrichment method can isolate heterogeneous and intact CTCs by precisely eliminating blood cells. The rising prevalence of the various types of cancer is expected to drive the market's overall growth.
According to the article published in Mindspace Oncology 2021, in 2020, liver cancer was the sixth most common cancer and the third leading cause of cancer deaths worldwide, with an estimated 905,677 new cases and 830,180 deaths. East Asia had the highest incidence, at 17.9 per 100,000 (26.9 in males and 8.9 in females), followed by Micronesia, northern Africa, Southeast Asia, and Melanesia. Moreover, the incidence rate was 6.9 per 100,00 in North America and 5.6 per 100,000 in western Europe. Overall, the incidence rate of liver cancer is approximately three times higher in males than in females.
Furthermore, according to an article published by the American Cancer Society in January 2022, kidney cancer is among the ten most common cancers in both men and women in the United States. Overall, the lifetime risk for developing kidney cancer in men is about 1 in 46, and in women is about 1 in 80, which is significantly high. Cancer prevention is one of the most significant challenges with this growing burden. The analysis of circulating tumor cells is a substantial aspect of monitoring disease progression or response to treatment, specifically as a companion diagnostic for new anticancer drugs and research into the mechanisms of disease progression.
In addition, negative enrichment has advantages over positive enrichment in isolating CTCs, owing to which the segment is expected to witness high growth over the forecast period. For instance, the study "Negative enrichment of circulating tumor cells from unmanipulated whole blood with a 3D printed device," published in October 2021, stated that the negative enrichment approach is advantageous because it leads to an unbiased detection of CTCs and also produces intact tumor cells free of attached immuno-agents, eliminating potential artifacts in downstream studies. Thus, the market is harmful to grow significantly with the advantages of negative enrichment methods over other enrichment approaches.
Thus, the studied segment is expected to contribute significantly to the market growth owing to the abovementioned factors.
North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period
North America is expected to contribute to the significant growth of the market owing to the factors such as the increasing burden of cancer, product approvals, and rising research and development activities.
For instance, according to the estimates of the 2022 American Cancer Society, Inc., about 236,740 new cases of lung cancer will be diagnosed in the country in 2022. The same source also states that 79,000 new cases of kidney cancer and 13,920 deaths will be reported in 2022 from Kidney cancer. The high burden of cancer is expected to boost the demand for CTC detection kits, thereby driving the market growth.
Additionally, product approvals in the studied market are further expected to drive market growth. For instance, in November 2020, the Food and Drug Administration (FDA) expanded the approved uses for a blood test, known as a liquid biopsy, that can help doctors pick the best treatments for some people with cancer. The test identifies cancer-related genetic changes in DNA from tumor cells released into the blood.
According to a study, "Cancer cells alter protein production machinery to hasten metastasis," published in February 2020, CTCs enriched from the blood of breast cancer patients have higher levels of ribosomal proteins (RP), and their presence is associated with increased disease aggressiveness and poor clinical outcomes. Thus, studies evaluating the presence of ribosomal proteins in CTCs will lead to an effective cancer diagnosis, thus, driving the market.
The United States has one of the highly successful products, the CellSearch Circulating Tumor Cell Kit, which was approved by the US Food and Drug Administration (FDA). The product has reimbursement facilities through various public and private payers in several states, such as Cigna Government Services, Noridian, and United Healthcare. Several universities across the United States have relied on CTCs applications to advance the practice of pathology and laboratory medicine. Thus, the market studied is expected to witness high growth over the forecast period owing to all the factors above.
Competitive Landscape
The market studied is a moderately consolidated market, owing to the presence of small and large market players. Some market players are Advanced Cell Diagnostics Inc., Aviva Biosciences, Biocept Inc., Creatv Micro Tech, Inc., LungLife AI Inc., Menarini Silicon Biosystems, and Miltenyi Biotec, Precision For Medicine (Formerly ApoCell), and Qiagen NV.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size by Value - USD Million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Advanced Cell Diagnostics Inc.
- Aviva Biosciences
- Biocept Inc.
- Creatv Micro Tech Inc.
- LungLife AI Inc.
- Menarini Silicon Biosystems
- Miltenyi Biotec
- Precision for Medicine (Formerly ApoCell)
- Qiagen NV
- BioChain Institute Inc.
- Thermofisher
- Sysmex Corporation
Methodology
LOADING...
